Geroscience-guided drug discovery

Target aging.Change the future
of disease.

Discovering gerotherapeutics for diseases that share the biological drivers of aging.

Explore the pipeline Our science
One biology. Multiple possibilities.

Many diseases.Shared biological roots.

Aging biology contributes to disease across tissues. We develop small-molecule approaches to these shared drivers.

Illustration of a tree rooted in aging, with branches leading to age-related diseases including cancer, dementia, diabetes, heart disease, and arthritis.
Disease areas

A broader viewof health.

Oncology is our lead program, with fibrosis and neurodegeneration in discovery. Each targets the senescent cells that build up in diseased and aging tissue.

Lead program, preclinical evaluation

Oncology

Cancer therapies can push tumor and stromal cells into senescence. Those cells can persist, fuel inflammation, and support relapse and resistance.

  • Bladder
  • Breast
  • Melanoma
  • Lung
  • Renal
Discovery

Fibrosis

Senescent cells sustain the pro-fibrotic signals behind progressive scarring of vital organs.

  • Liver
  • Lung
  • Kidney
Discovery

Neurodegeneration

Senescent glia accumulate in the aging brain and are linked to chronic neuroinflammation.

  • Central nervous system

Model selection and evaluation progress vary by program.

Explore our pipeline
Our approach

Predictionsmeet biology.

Drug discovery works best when predictions meet biology. We connect screening, molecular design, and AI with experimental evaluation.

Multi-well screening plates
Drug screening and high-content imaging

Find activity.Understand the cellular response.

Chemical-library screening and quantitative imaging identify promising compounds and characterize their effects in relevant cellular models.

Inside our technology

A cycle, not a sequence: results from living systems return to screening and design.

Together, further

Advance the science.Expand the possibilities.

Connect with us